아토피피부염에 대한 Pedunculagin의 치료효능에 관한 연구 = A Study for the Therapeutic Efficacy of Pedunculagin for Atopic Dermatitis

다국어 초록 (Multilingual Abstract)

Backgrounds: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder with increasing prevalence. Experimental animal model are indispensable tools to study the pathogenic mechanisms and to test novel therapeutic approaches in vivo. AD-like lesions can be induced experimentally in NC/Nga mice. Pedunculagin, an ellagitannin purified from Alnus hirsuta var. microphylla, Betulaceas, is a novel immunomodulator.

Object: To evaluate the therapeutic efficacy of pedunculagin for AD-like dermatits of NC/Nga mice by clinical method and noninvasive methods.

Method: AD-like lesions can be induced experimentally in NC/Nga mice using 2,4,6-Trinirtochlorobenzene (TNCB). Left upper back remained untreated and right upper back was administered by vehicle. Left lower back was administered by 0.1% pedunculagin and right lower back was administered by 0.5% pedunculagin as daily application for 4 weeks. Clinical severity scores of the dermatitis and ear thickness, transepidermal water loss (TEWL), water holding capacity (WHC), pH, skin roughness were measured noninvasively at baseline and at 1day, 3day, 1weak, 2weak, 4weak after pedunculagin and vehicle application respectively.

Results: AD has been induced using TNCB successfully. We evaluated the therapeutic efficacy of pedunculagin for atopic dermatitis using evaluation methods of the clinical severity score and noninvasive biomedical engineering tools such as Corneometer？, pH-meter？, Evaporimeter？, and SOT statistically. The therapeutic efficacy of pedunculagin for atopic dermatitis was confirmed using Corneometer？, Evaporimeter？, and SOT especially.

Conclusions: These results suggest that pedunculagin might improve the disruption of permeability barrier with improvement of the water holding capacity of the stratum corneum